Agios Pharmaceuticals

Rare‑disease positioning confers strong pricing power: U.S. WAC for AQVESME is disclosed around $425,000 annually, while PYRUKYND’s WAC per 56‑tablet carton implies a high annualized list price at typical dosing.

Orphan designations and limited branded alternatives in PK deficiency support pricing sustainability, and the thalassemia label addresses both NTDT and TDT populations. Offsets include potential net price pressure from ex‑U.S. HTA negotiations, REMS administrative burden that can slow initiation, and payer re‑verification cycles.

Still, the low absolute patient counts and disease burden provide headroom for value‑based positioning, especially if real‑world outcomes mirror Phase 3.